ANDA 203605, held by MCPRF. Sodium Fluoride F-18.
As of Nov 22, 2026, ANDA 203605 (Sodium Fluoride F-18), held by MCPRF, was first approved by FDA on Jun 28, 2013, with 0 approved supplements and 0 published complete response letters.
Sodium Fluoride F 18 Injection USP is indicated for diagnostic positron emission tomography (PET) imaging of bone to define areas of altered osteogenic activity. Sodium Fluoride F 18 Injection USP is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 28, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Sodium Fluoride F-1810-91.5mCi/ML · injectable;intravenous | Sodium Fluoride F-18 | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters